atezolizumab sold brand name tecentriq monoclonal antibody medication used treat urothelial carcinoma nonsmall cell lung cancer nsclc small cell lung cancer sclc hepatocellular carcinoma alveolar soft part discontinued use triplenegative breast cancer fully humanized engineered monoclonal antibody isotype protein programmed cell deathligand common side effects used include tiredness reduced appetite nausea vomiting cough difficulty breathing diarrhea rash fever pain back joints muscles bones weakness itching urinary tract common side effects used cancer medicines include peripheral neuropathy nerve damage hands feet nausea anemia low red blood cell counts neutropenia low white blood cell counts thrombocytopenia low platelet counts rash tiredness constipation reduced appetite diarrhea atezolizumab first inhibitor approved us food drug administration european union atezolizumab indicated treatment urothelial carcinoma nonsmall cell lung cancer small cell lung cancer hepatocellular carcinoma urothelial carcinoma triplenegative breast longer indicated triplenegative breast united states atezolizumab indicated treatment nonsmall cell lung cancer small cell lung cancer hepatocellular carcinoma melanoma alveolar soft part indication urothelial carcinoma withdrawn november common adverse effects studies fatigue decreased appetite nausea infections urinary tract infection common severe adverse atezolizumab blocks interaction programmed cell death protein receptors highly expressed certain tumors thought lead reduced activation immune cells cytotoxic tcells particular might otherwise recognize attack inhibition atezolizumab remove inhibitor effect thereby engender antitumor response one several ways block inhibitory signals related tcell activation general strategy known immune checkpoint cancers notably bladder probability benefit related expression cancers expression still respond many without expression clinical trials immunotherapy several types solid investigation april roche announced atezolizumab granted fast track status lung cancer us food drug administration may fda granted accelerated approval atezolizumab locally advanced metastatic urothelial carcinoma treatment failure cisplatinbased confirmatory trial convert accelerated approval full approval failed achieve primary endpoint overall fda altered use atezolizumab firstline treatment metastatic bladder cancer people cant receive cisplatinbased chemotherapy high levels may atezolizumab approved fda treatment people locally advanced metastatic urothelial carcinoma disease progression following platinumcontaining chemotherapy disease progression within twelve months neoadjuvant adjuvant treatment platinumcontaining may atezolizumab failed phase iii trial second line bladder safety efficacy atezolizumab studied people urothelial tumors temporarily shrank minority participants people likely benefit tumor expressed trial conducted united states canada spain france great britain germany italy october atezolizumab approved fda treatment people metastatic nonsmall cell lung cancer nsclc whose disease progressed following platinumcontaining people egfr alk genomic tumor aberrations disease progression fdaapproved therapy aberrations prior receiving approval based two international randomized openlabel clinical trials oak poplar demonstrated consistent results efficacy safety total participants compared docetaxel treatment atezolizumab intended participants population two trials resulted month improvement overall survival os atezolizumab approved medical use european union september may use atezolizumab combination bevacizumab avastin standard chemotherapy people lung cancer granted priority august fda updated prescribing information atezolizumab require use fdaapproved companion diagnostic test determine levels tumor tissue people locally advanced metastatic urothelial cancer september announced atezolizumab prolongs survival extensive stage sclc treatment according study results presented world conference lung cancer wclc toronto canadamedical citation needed october combined clinical trial drug nabpaclitaxel people advanced tnbc atezolizumab combination bevacizumab paclitaxel carboplatin approved united states december firstline treatment people metastatic nonsquamous nonsmall cell lung cancer nsq nsclc egfr alk genomic tumor approval based trial openlabel randomized threearm trial enrolling participants receiving firstline treatment metastatic nsq march approved united states combination paclitaxel proteinbound adults unresectable locally advanced metastatic tnbc whose tumors express stained tumorinfiltrating immune cells ic intensity covering tumor area determined fdaapproved fda also approved ventana assay companion diagnostic device selecting tnbc patients approval based multicenter international doubleblinded placebocontrolled randomized trial included participants unresectable locally advanced metastatic tnbc received prior chemotherapy metastatic participants randomized receive either atezolizumab mg placebo intravenous infusions days every cycle plus paclitaxel proteinbound administered via intravenous infusion days every also march approved united states combination carboplatin etoposide firstline treatment adults extensivestage small cell lung cancer approval based randomized multicenter doubleblind placebocontrolled trial participants essclc received prior chemotherapy extensive stage disease ecog performance status december atezolizumab combination paclitaxel proteinbound carboplatin approved fda firstline treatment adults metastatic nonsquamous nonsmall cell lung cancer nsclc egfr alk genomic tumor efficacy evaluated multicenter randomized openlabel trial participants stage iv nonsquamous nsclc received prior chemotherapy metastatic disease could received prior egfr alk kinase inhibitor trial randomized participants itt either receive atezolizumab paclitaxel proteinbound carboplatin followed singleagent atezolizumab receive paclitaxel proteinbound carboplatin followed maintenance pemetrexed investigators may atezolizumab approved fda firstline treatment adults metastatic nonsmall cell lung cancer nsclc whose tumors high expression stained tumor cells tc stained tumorinfiltrating immune cells ic covering tumor area ic egfr alk genomic tumor efficacy evaluated multicenter international randomized openlabel trial participants stage iv nsclc whose tumors express tc ic received prior chemotherapy metastatic participants randomized receive atezolizumab mg every three weeks disease progression unacceptable toxicity platinumbased also may atezolizumab combination bevacizumab approved fda people unresectable metastatic hepatocellular carcinoma received prior systemic efficacy investigated multicenter international openlabel randomized trial participants locally advanced unresectable metastatic hepatocellular carcinoma received prior systemic total participants randomized receive either atezolizumab mg intravenous infusion iv followed bevacizumab mgkg iv day every weeks sorafenib orally twice july approved united states combination cobimetinib vemurafenib treatment people braf mutationpositive unresectable metastatic efficacy combination cobimetinib vemurafenib evaluated doubleblind randomized placebocontrolled multicenter trial cycle cobimetinib vemurafenib participants received atezolizumab mg intravenous infusion every weeks combination cobimetinib mg orally daily vemurafenib mg orally twice daily placebo combination cobimetinib mg orally daily days days vemurafenib mg orally twice randomized patients stage iv nsclc expression atezolizumab single agent chemotherapy used cisplatin carboplatin combined gemcitabine patient squamous cell nsclc pemetrexed patients nonsquamous atezolizumab better tolerated chemotherapy subgroup patients egfr alk wildtype tumors stained tumor cells patients overall survival months atezolizumab months fda approval patients stained tumor cells stained tumorinfiltrating immune cells covering tumor area egfr alk genomic tumor openlabel phase iii trial compared atezolizumab combination carboplatin plus nabpaclitaxel chemotherapy chemotherapy alone firstline treatment metastatic nonsquamous half patients negative tumors median overall survival months atezolizumab plus chemotherapy group months chemotherapy group hr p subgroup analysis showed progression free survival benefit trend toward overall survival benefit expression randomized patients nsq nsclc treatment chemotherapy plus bevacizumab chemotherapy plus atezolizumab chemotherapy plus bevacizumab chemotherapy used carboplatin median overall survival months patients treated chemotherapy plus bevacizumab without atezolizumab median os atezolizumab chemotherapy alone months raising question regard added value bevacizumab combination general patients importantly patients baseline liver metastases improved overall survival atezolizumab bevacizumab chemotherapy combination compared bevacizumab chemotherapy alone median os months respectively hr improvement overall survival observed patients liver metastasis treated chemotherapy atezolizumab compared patients treated chemotherapy recent report safety patientreported outcomes atezolizumab plus chemotherapy bevacizumab shows drug combination seems tolerable manageable patients nsq nsclc baseline liver metastases combination chemotherapy atezolizumab bevacizumab could option consider first august great britains healthcare products regulatory agency mhra approved subcutaneous atezolizumab indications intravenous formulation drug approved including select types lung bladder breast liver cancers receiving approval nhs england stated hundreds patients treated immunotherapy set receive skin injections atezolizumab eventually lead time cancer atezolizumab treatment costs average per month united states depending dosage despite updated data showing people extensive stage small cell lung cancer survived months compared received chemotherapy canadian regulators rejected funding atezolizumab treat extensive stage smallcell lung cancer costly followed united kingdom also citing drugs however uk reversed previous decision approved tecentriq extensive stage small cell lung cancer price reconsideration may clinical trials colorectal cancer melanoma breast cancer nonsmallcell lung carcinoma bladder cancer renal cell update promising results observed melanoma nonsmallcell lung bladder phase trial reported objective response rate metastatic triplenegative breast atezolizumab trial several types cancer pancreatic cancer gastric cancer ovarian update httpsenwikipediaorgwikiatezolizumab